Results 21 to 30 of about 2,525 (153)

Predicting the Effects of Carbapenem/Carbapenemase Inhibitor Combinations against KPC-Producing Klebsiella pneumoniae in Time-Kill Experiments: Alternative versus Traditional Approaches to MIC Determination

Antibiotics, 2021
Traditionally, the antibacterial activity of β-lactam antibiotics in the presence of β-lactamase inhibitors is determined at the fixed inhibitor concentration.
Alla V. Filimonova, Maria V. Golikova, Elena N. Strukova, Yury A. Portnoy, Anastasiya A. Kuznetsova, Stephen H. Zinner   +5 more
doaj   +1 more source

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus [PDF]

Scientific Reports, 2020
AbstractInfections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic interventions. Here we report a prospective advance in the treatment of M.
Rose C. Lopeman, James Harrison, Daniel L. Rathbone, Maya Desai, Peter A. Lambert, Jonathan A. G. Cox   +5 more
openaire   +3 more sources

Pharmacodynamics of Doripenem Alone and in Combination with Relebactam in an In Vitro Hollow-Fiber Dynamic Model: Emergence of Resistance of Carbapenemase-Producing Klebsiella pneumoniae and the Inoculum Effect

Antibiotics, 2023
The emergence of bacteria resistant to beta-lactam/beta-lactamase inhibitor combinations is insufficiently studied, wherein the role of the inoculum effect (IE) in decreased efficacy is unclear.
Elena N. Strukova, Maria V. Golikova, Svetlana A. Dovzhenko, Mikhail B. Kobrin, Stephen H. Zinner   +4 more
doaj   +1 more source

Molecular Basis of Class A β-Lactamase Inhibition by Relebactam [PDF]

Antimicrobial Agents and Chemotherapy, 2019
β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) producers, especially strains carrying the widely disseminated class A enzymes, are required.
Catherine L. Tooke, Philip Hinchliffe, Pauline A. Lang, Adrian J. Mulholland, Jürgen Brem, Christopher J. Schofield, James Spencer   +6 more
openaire   +5 more sources

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

International Journal of Infectious Diseases, 2019
Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin.
Pratik Bhagunde, Zufei Zhang, Fred Racine, Donna Carr, Jin Wu, Katherine Young, Matthew L. Rizk   +6 more
doaj   +1 more source

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications [PDF]

Clinical Therapeutics, 2020
Imipenem/cilastatin/relebactam has shown efficacy in complicated intra-abdominal and urinary tract infections in the RESTORE IMI-1 study, and it was recently approved by the US Food and Drug Administration. A press release announced that another Phase III study (RESTORE IMI-2) in patients with hospital-acquired and ventilator-associated pneumonia has ...
Islam M, Ghazi, Wasim S, El Nekidy, Ayush, Sood, Amanpreet, Dulku, Radha, Patel, Krishna, Patel, Pengfei, Li   +6 more
openaire   +2 more sources

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases [PDF]

Journal of Antimicrobial Chemotherapy, 2020
Abstract Background ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via loss of OprD, isolates producing ESBLs are ...
Shazad Mushtaq, Danièle Meunier, Anna Vickers, Neil Woodford, David M Livermore   +4 more
openaire   +4 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Antibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin, Sandrine Bernabeu, Cécile Emeraud, Thierry Naas, Delphine Girlich, Agnès B. Jousset, Laurent Dortet   +6 more
doaj   +1 more source